BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37738978)

  • 1. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.
    Jafari S; Molavi O; Kahroba H; Hejazi MS; Maleki-Dizaji N; Barghi S; Kiaie SH; Jadidi-Niaragh F
    Cell Mol Life Sci; 2020 Oct; 77(19):3693-3710. PubMed ID: 32006051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
    De Velasco MA; Kura Y; Fujita K; Uemura H
    Int J Urol; 2024 Apr; 31(4):307-324. PubMed ID: 38167824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumor microenvironment and immune responses in prostate cancer patients.
    Kwon JTW; Bryant RJ; Parkes EE
    Endocr Relat Cancer; 2021 Jul; 28(8):T95-T107. PubMed ID: 34128831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer.
    Dorff TB; Narayan V; Forman SJ; Zang PD; Fraietta JA; June CH; Haas NB; Priceman SJ
    Clin Cancer Res; 2022 Feb; 28(4):576-584. PubMed ID: 34675084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicine sheds new light on cancer immunotherapy.
    Yu Y; Feng L; Liu Z
    Med Rev (2021); 2023 Apr; 3(2):188-192. PubMed ID: 37724084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Ovarian Cancer: Disappointing or Promising?
    Deng M; Tang F; Chang X; Liu P; Ji X; Hao M; Wang Y; Yang R; Ma Q; Zhang Y; Miao J
    Mol Pharm; 2024 Feb; 21(2):454-466. PubMed ID: 38232985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically relevant humanized mouse models of metastatic prostate cancer facilitate therapeutic evaluation.
    Kostlan RJ; Phoenix JT; Budreika A; Ferrari MG; Khurana N; Choi JE; Juckette K; Mahapatra S; McCollum BL; Moskal R; Mannan R; Qiao Y; Vander Griend DJ; Chinnaiyan AM; Kregel S
    Mol Cancer Res; 2024 May; ():. PubMed ID: 38820127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients.
    Roumeliotou A; Strati A; Chamchougia F; Xagara A; Tserpeli V; Smilkou S; Lagopodi E; Christopoulou A; Kontopodis E; Drositis I; Androulakis N; Georgoulias V; Koinis F; Kotsakis A; Lianidou E; Kallergi G
    Cells; 2024 May; 13(9):. PubMed ID: 38727318
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Fan Y; Ge Y; Niu K; Li Y; Qi LW; Zhu H; Ma G
    Front Immunol; 2024; 15():1364329. PubMed ID: 38698844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
    Kim TJ; Koo KC
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach.
    Sridaran D; Bradshaw E; DeSelm C; Pachynski R; Mahajan K; Mahajan NP
    Cell Rep Med; 2023 Oct; 4(10):101199. PubMed ID: 37738978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
    Zorko NA; Ryan CJ
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
    Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
    Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.